Bharat Book

Orphan Drugs Partnering Terms and Agreements

Press Release   •   Dec 13, 2013 10:58 IST

Dec 13, 2013 : Bharat Book Bureau presents the new report, on 'Orphan Drugs Partnering Terms and Agreements' provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan drugs technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 140 links to online copies of actual orphan drugs deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of orphan drugs dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in orphan drugs dealmaking since 2007, including details of disclosed headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading orphan drugs deals since 2007. Deals are listed by headline value, signed by bigp harma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of orphan drugs deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of orphan drugs deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 and 7 provides a comprehensive and detailed review of orphan drugs partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type . Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in orphan drugs partnering and dealmaking since 2007.

In addition, a comprehensive appendix is provided organized by orphan drugs partnering company A-Z , deal type definitions and orphan drugs partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan drugs technologies and products.

Report scope

Orphan Drugs Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to orphan drugs trends and structure of deals entered into by leading companies worldwide.

Orphan Drugs Partnering Terms and Agreements includes:

Trends in orphan drugs dealmaking in the biopharma industry since 2007
Analysis of orphan drugs deal structure
Access to headline, upfront, milestone and royalty data
Access to 140 orphan drugs deal records
The leading orphan drugs deals by value since 2007

In Orphan Drugs Partnering Terms and Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Table of contents :

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in orphan drugs dealmaking
2.1. Introduction
2.2. Orphan drugs partnering over the years
2.3. Bigpharma orphan drugs dealmaking activity
2.4. Big biotech orphan drugs dealmaking activity
2.5 Most active orphan drugs dealmakers
2.6. Orphan drugs partnering by deal type
2.7. Orphan drugs partnering by industry sector type
2.8. Orphan drugs partnering by stage of development
2.9. Orphan drugs partnering by therapy area
2.10. Orphan drugs partnering by orphan drug technology type
2.11. Average deal terms for orphan drugs partnering
2.11.1 Orphan drugs headline values
2.11.2 Orphan drugs upfront payments
2.11.3 Orphan drugs milestone payments
2.11.4 Orphan drugs royalty rates
2.12. The anatomy of orphan drug partnering
2.12.a. Case study 1: Xoma, Servier- January 2011
2.12.b. Case study 2: Epicept, Meda: January 2010

Chapter 3 – Leading orphan drugs deals
3.1. Introduction
3.2. Top orphan drugs deals by value
3.3. Top orphan drugs deals involving big pharma or big biotech

Chapter 4 – Bigpharma orphan drugs deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Big pharma orphan drugs partnering company profiles

Chapter 5 – Bigbiotech orphan drugs deals
5.1. Introduction
5.2. How to use bigbiotech partnering deals
5.3. Bigbiotech orphan drugs partnering company profiles
 

For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/orphan-drugs-partnering-terms-and-agreements.html

Related link :  http://www.bharatbook.com/market-research-report/pharmaceuticals-and-healthcare.html

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Email: info@bharatbook.com 
Website: www.bharatbook.com 
Follow us on twitter: https://twitter.com/researchbook 
Follow us on linked in : http://www.linkedin.com/company/bharat-book-bureau 
Our Blog : http://blog.bharatbook.com/ 


Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.